Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir

Executive Summary

Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.

You may also be interested in...



Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab

GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.

Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US

A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel